State of Alaska Department of Revenue Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA)

State of Alaska Department of Revenue lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 43,883 shares of the company’s stock after selling 685 shares during the period. State of Alaska Department of Revenue’s holdings in Moderna were worth $1,824,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in MRNA. Arkadios Wealth Advisors increased its stake in Moderna by 2.2% in the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the period. Knuff & Co LLC grew its holdings in shares of Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Moderna by 7.9% in the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after buying an additional 245 shares during the period. Larson Financial Group LLC raised its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock valued at $347,000 after buying an additional 322 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Wolfe Research started coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Bank of America reduced their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday. Finally, Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $66.89.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $30.93 on Wednesday. The firm has a market cap of $11.90 billion, a P/E ratio of -5.31 and a beta of 1.59. The company has a 50 day moving average of $39.77 and a 200 day moving average of $56.76. Moderna, Inc. has a twelve month low of $30.70 and a twelve month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last ninety days. 15.20% of the stock is currently owned by corporate insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.